Opinion|Videos|June 24, 2024
Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.
Advertisement
Episodes in this series
- Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
Tannir et al., ASCO GU 2024 Abstract 363 ) - What insights do the recent HRQoL data provide? (
Cella et al., Oncologist Jan 2024 )
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
- Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.
- CheckMate 9ER nivo + cabo
- 55-month follow up (
Bourlon et al., ASCO GU 2024 Abstract 362) - HRQoL (
Bedke et al., ASCO GU 2024 Abstract 384 ) - Partitioned 4-year OS (
Mantia et al., ASCO 2024 Abstract 4507 )
Advertisement
Related to this article
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
3
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
4
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
5